VXRT

Vaxart Inc

VXRT.US vaxart.com + Research + Basket
CIK 0000072444
Employees 65
Phone 650 550 3500
Fiscal year end December
IPO Feb 12, 2018
Address 310 Utah Avenue, South San Francisco, CA, United States, 94080
0.40
+0.00 (+0.00%)
USD · PINK
52-week range
0.33
0.84
Trading at 14% of the 52-week range
Market Cap
97.48M
P/E Ratio
2.35
Forward P/E
42.74
Book Value
0.34
Div. Yield
N/A
% Institutions
0.055%
% Insiders
1.46%

1 Year

+17.6%

3 Year

-44.1%

10 Year

-97.0%
Description

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Actions

Add an action for VXRT.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Steven Lo President, CEO & Director 1967
Dr. Sean N. Tucker Ph.D. Senior VP & Chief Scientific Officer 1968
Dr. James F. Cummings M.D. Chief Medical Officer 1966
Mr. Jeroen Grasman M.B.A. CFO, Principal Accounting Officer & Principal Financial Officer 1970
Mr. Todd Lopeman Chief Technology Officer NA
Mr. Edward B. Berg Senior VP & General Counsel 1964
Ms. Laurie Hastings Senior Vice President of Human Resources NA
Dr. Rajesh Kapoor Ph.D. Senior Vice President of Quality NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
May 19, 2025 Steven Lo N/A Purchase 100.00K $0.49 $49.00K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Heritage Wealth Advisors, LLC 29.66K Mar 31, 2026 0.01% $0.00 14.13%
LVM Capital Management Ltd. 25.00K Jun 30, 2026 0.01% $0.00 0.00%
Kingswood Wealth Advisors LLC 10.01K Jun 30, 2026 0.00% $0.00 0.00%
Golden State Equity Partners 2.00K Mar 31, 2026 0.00% $0.00 0.00%
Archer Investment Corporation 15.00 Jun 30, 2026 0.00% $0.00 0.00%
First Command Advisory Services, Inc. 0.00 Jun 30, 2026 0.00% $0.00 -100.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 LUX IM Global Medtech HX 64.91K 0.03% ▲ 0.00% Aug 31, 2026
2 Guggenheim Active Allocation Fund 1.43K 0.00% ▲ 100.00% May 31, 2026

Financial Highlights

▼
Market Cap: $97.48M
EBITDA: $45.62M
P/E Ratio: $2.35
Book Value: $0.34
Earnings/Share: $0.17
Profit Margin: 15.88%
Operating Margin: -48.45%
ROA (TTM): 15.04%
ROE (TTM): 66.97%
Revenue (TTM): $243.06M
Revenue/Share (TTM): $1.03
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -31.60%

Valuation Metrics

Enterprise Value: $43.77M
Trailing P/E: 2.35
Forward P/E: 42.74

Shares Statistics

Shares Outstanding: 243.70M
Shares Float: 239.25M
% Insiders: 1.46%
% Institutions: 0.055%
Shares Short: 21.17M
Shares Short (Prior Month): 14.68M
Short Ratio: 1.87
Short % Float: 7.51%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$237.26M
Gross Profit
subtotal
$237.26M
SG&A
adjust
$-17.61M
R&D
adjust
$-201.58M
Operating Income
subtotal
$18.07M
Other / Non-Operating Items
adjust
$-1.75M
Net Income
subtotal
$16.33M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about VXRT.US!